Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000897491

Apexbio Technology LLC Anti-Amyloid Beta Solanezumab
SDP

Catalog No. 5000897491
Encompass_Preferred

Anti-Amyloid Beta Antibody (Solanezumab) (CAS No 955085-14-0) is a monoclonal antibody used in Alzheimer s research originating from Eli Lilly and Company It specifically targets amyloid beta plaques implicated in Alzheimer s pathogenesis by binding to soluble monomers thereby reducing plaque formation Solanezumab s action is primarily observed in the modulation of amyloid beta clearance mechanisms within the central nervous system In vitro activity typically occurs in the nanomolar range reflecting its high affinity and specificity for amyloid beta peptides It s commonly applied in cell models and animal studies to evaluate therapeutic potential particularly in transgenic mice expressing human amyloid precursor protein Additionally Solanezumab is prominent in drug screening processes for Alzheimer s therapeutics Experimental concentrations typically depend on the specific research design ensuring flexibility in dose-response assessments across different methodologies

Catalog No. 50-008-97491 Supplier Apexbio Technology LLC Supplier No. F153450
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Anti-Amyloid Beta Antibody (Solanezumab) (CAS No 955085-14-0) is a monoclonal antibody used in Alzheimer s research originating from Eli Lilly and Company It specifically targets amyloid beta plaques implicated in Alzheimer s pathogenesis by binding to soluble monomers thereby reducing plaque formation Solanezumab s action is primarily observed in the modulation of amyloid beta clearance mechanisms within the central nervous system In vitro activity typically occurs in the nanomolar range reflecting its high affinity and specificity for amyloid beta peptides It s commonly applied in cell models and animal studies to evaluate therapeutic potential particularly in transgenic mice expressing human amyloid precursor protein Additionally Solanezumab is prominent in drug screening processes for Alzheimer s therapeutics Experimental concentrations typically depend on the specific research design ensuring flexibility in dose-response assessments across different methodologies

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.